Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy.
Devon MillerJonathan A LivingstonYeonhee ParkKristi PoseySonia GodboleKeith M SkubitzSteven I RobinsonMark AgulnikLara E DavisBrian Andrew Van TineAngela C HirbeAmanda ParkesPublished in: Cancer medicine (2022)
In this multi-institutional study of sarcoma chemotherapy regimens administered during pregnancy, we found a high rate of fetal demise that was seen only in patients receiving both doxorubicin and ifosfamide and statistically more likely with chemotherapy initiation earlier in the second trimester. While limited by a small sample size, our study represents the largest study of sarcoma patients that received anthracyclines and/or ifosfamide in pregnancy thus far reported and supports development of an international registry to study concerns raised by our study.